Dexcom has received FDA clearance for Smart Basal, its new continuous glucose monitor (CGM) integrated basal insulin dosing optimizer for adults with type 2 diabetes who use long acting glargine U-100 insulin. This clearance makes Smart Basal the first tool of its kind to use full CGM data to guide daily basal dose adjustments.
Smart Basal works inside the Dexcom G7 15 Day app. It pulls in CGM data along with the user’s logged injections and then gives dose recommendations once a day. Instead of relying on a single fasting reading, it looks at the person’s entire glucose profile. If it detects lows, the system automatically suggests a lower dose based on what the provider has set. When glucose levels stay within a target range, the app signals that the optimal dose has been reached.
Dexcom says the goal is to make starting basal insulin less stressful. Many people struggle with fear of hypoglycemia and slow titration schedules, so by giving users and providers clearer guidance and more data, Smart Basal may shorten that process and help people feel more confident with insulin management.
Smart Basal will be added to the Dexcom G7 15 Day app after launch in the United States. Providers will be able to prescribe and configure it through Dexcom Clarity. The company also says it is evaluating international rollout.
This clearance comes at a time when Dexcom is under increased attention. A potential class action lawsuit claims the G7 produced false readings and missed urgent alerts. We recently spoke with Dexcom about reliability, ongoing recalls and upcoming improvements. The company is also broadening its focus, including new metabolic health offerings like Dexcom Stelo syncing with the Oura Ring.
Smart Basal fits into that broader picture of Dexcom trying to build smarter, more connected tools across the spectrum of diabetes and metabolic care. If real world performance matches the promise, it could become an important step toward more personalized insulin dosing for people with type 2 diabetes.
Want more?
For the latest diabetes tech, join our free newsletter.
If you like our content and want more, join Diabetech All Access—unlocking monthly Live Q&As, exclusive stories and industry analysis. Your support helps sustain our independent journalism and keeps this platform thriving.
Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.
